Drug Interaction Report

GENERALLY AVOID: Coadministration with potent or moderate inhibitors of CYP450 2C9 may significantly increase the plasma concentration of meloxicam, which has been shown to be primarily metabolized by this isoenzyme. In a study of healthy volunteers, voriconazole, a weak CYP450 2C9 inhibitor increased the systemic exposure of meloxicam by 47% and prolonged the average meloxicam half-life by 51%. Clinical data for meloxicam use in combination with other more potent CYP450 2C9 inhibitors are unavailable.

MANAGEMENT: Concomitant use of meloxicam with potent or moderate CYP450 2C9 inhibitors should generally be avoided. If coadministration is required, monitor patients for NSAID-related side effects and toxicity including gastrointestinal bleeding or perforation. Dose adjustment of meloxicam may be warranted.